Progression risk factors of ulcerative proctitis.
Gaweł K, Dąbkowski K, Zawada I, Starzyńska T.
Scand J Gastroenterol. 2022 Dec;57(12):1406-1411. doi: 10.1080/00365521.2022.2094726. Epub 2022 Jul 6.
Management of proctitis in ulcerative colitis and the place of biological therapies.
De Deo D, Dal Buono A, Gabbiadini R, Spaggiari P, Busacca A, Masoni B, Ferretti S, Bezzio C, Armuzzi A.
Expert Opin Biol Ther. 2024 Jun;24(6):443-453. doi: 10.1080/14712598.2024.2369189. Epub 2024 Jun 17.
Long-term outcome of ulcerative proctitis.
Ungar B, Kopylov U.
United European Gastroenterol J. 2020 Oct;8(8):847-848. doi: 10.1177/2050640620948795. Epub 2020 Aug 2.
Systematic review of therapies for refractory ulcerative proctitis.
Raja SS, Bryant RV, Costello SP, Barnett M, Schubert J, Rayner CK.
J Gastroenterol Hepatol. 2023 Apr;38(4):496-509. doi: 10.1111/jgh.16111. Epub 2023 Feb 6.
Ulcerative proctitis: an update on the pharmacotherapy and management.
Gecse KB, Lakatos PL.
Expert Opin Pharmacother. 2014 Aug;15(11):1565-73. doi: 10.1517/14656566.2014.920322. Epub 2014 May 16.
Ulcerative proctitis.
McKechnie JC, Bynum TE, Bentlif PS, Lanza FL.
South Med J. 1974 Sep;67(9):1052-6. doi: 10.1097/00007611-197409000-00012.
Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository.
Kato S, Ishibashi A, Kani K, Yakabi K.
Digestion. 2018;97(1):59-63. doi: 10.1159/000484224. Epub 2018 Feb 1.
Ulcerative proctitis.
Buls J.
Aust N Z J Surg. 1980 Apr;50(2):179-80. doi: 10.1111/j.1445-2197.1980.tb06662.x.
Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review.
Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L.
J Crohns Colitis. 2022 Jul 14;16(6):922-930. doi: 10.1093/ecco-jcc/jjab218.
Ulcerative proctitis: Challenges for clinical management.
Caron B, Peyrin-Biroulet L.
J Gastroenterol Hepatol. 2023 Jul;38(7):1192. doi: 10.1111/jgh.16216. Epub 2023 May 11.
